Utilize este identificador para referenciar este registo:
|Título:||Biocompatibility Assessment of Polymeric Nanoparticle Carriers for Drug Delivery in Human Osteoblasts|
Silva, Maria João
|Resumo:||Bone infections after prosthetic surgery represent a painful and costly process that should be prevented. The use of nanocarriers as efficient drug-delivery systems represents an innovative strategy to reduce systemic toxicity and avoid antimicrobial resistance. Still, great efforts are required to ensure the biocompatibility and safety of new nanocarriers before their medical application. In this work, the FDA-approved polymers poly(methyl methacrylate) (PMMA), and Eudragit RL 100 (Eud) were used to obtain two sets of nanoparticles, plain PMMA and PMMA-Eud (50:50). Their biocompatibility was assessed in a normal and differentiated human osteoblast cell line. The nanoparticles synthesis was conducted by a previously optimized methodology and their physicochemical properties, including size distribution, surface charge, morphology and aggregation/agglomeration states, were analysed during different preparation steps. Furthermore, the cell uptake and cytotoxicity as well as and their potential to produce reactive oxygen species (ROS) were also studied. Cell assays were performed following exposure of MG63 (ATCC®CRL-1427™) under normal and differentiation culture conditions, to a concentration range of both polymeric nanoparticles. The results of the uptake studies confirmed that both nanoparticles are internalized by osteoblasts. For both formulations, neither a significant decrease in cell viability nor oxidative stress induction was observed. The comparative analysis of data obtained in undifferentiated osteoblast and in those under differentiation conditions showed similar effects being the latter slightly less sensitive to the nanoparticles toxicity. Based on the reported data, PMMA and PMMA-Eud can be described as biocompatible nanomaterials and be further explored in a perspective of potential carriers for drug delivery, reducing adverse effects of conventional treatments. However, another key property i.e., genotoxicity, needs to be assessed before ensuring their safety for human health. This approach isn’t only relevant for understanding the nano-bio interface by disclosing how physicochemical features relate to toxicological events, but also to support the safe-by-design concept.|
|Aparece nas colecções:||DGH - Posters/abstracts em congressos nacionais|
Ficheiros deste registo:
|poster KDias_final.pdf||1,8 MB||Adobe PDF||Ver/Abrir Acesso Restrito. Solicitar cópia ao autor!|
Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.